Contact Us

Contact Person : Michael Liu

Phone Number : +86-13631598551

Free call

810nm Photobiomodulation Machine For PBM Dementia Treatment

Minimum Order Quantity : 1 Price : negotiable
Packaging Details : 1pcs/box Delivery Time : 3-7work days
Payment Terms : L/C, D/A, D/P, T/T, Western Union, MoneyGram,PayPal Supply Ability : 1000
Place of Origin: China Brand Name: SSCH
Certification: CE Model Number: GY-PDT1

Detail Information

Product Name:: Blood Photobiomodulation Therapy Machine Function 1: Treat Ischemic Stroke, Traumatic Brain Injury,
LED Quantity:: 256pcs Power 1:: 60 MW Per LED, Total 15 W
Certificate:: CE Color:: White
Function 2:: Alzheimer's Disease, Parkinson's Diseas Wavelength:: 810 Nm
Power 2:: 24 MW/cm2 OEM:: Supported
High Light:

810nm Photobiomodulation Machine

,

60 mW/LED Photobiomodulation Machine

,

15W Photobiomodulation Helmet

Product Description

Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia) (PBM Dementia)

Compared with other therapy method, like drugs, light therapy is the most safe and no side effects way for treatment.
Light therapy was known in medical field for a long time, especially for the red light and infrared.


All our clients feel good spirit and comfortable after using.


Our device works with 810nm infrared, it can extend through the skull into the brain, offers an unique array of neurological benefits. It usually be used for treating metastatic lesions in deep tissues as well as in bones. And also be used for cancer cell imaging, as well as circulating tumor cell detection and destruction.

 

1.The 810 nm wavelength has the ability to extend through the skull to the brain, promoting recovery from traumatic brain injury and reducing long-term nerve damage.
2.810nm wavelength can help patients with severe depression and anxiety
3. NIR light is absorbed by cytochrome C oxidase in mitochondria.
4. Increased blood flow, energy, neuroprotection and less inflammation.
5. treat traumatic (stroke, TBI), neurodegenerative and psychiatric diseases.

1. Introduction

Over the past two decades, brain photobiomodulation (PBM) therapy has been introduced as an innovative modality for the stimulation of neural activity in order to improve brain function. This light-based technique involves exposure of neural tissue to a low fluence of light (ranging from < 1 to >20 J/cm2, and at wavelengths ranging from red to near-infrared (NIR) (600 to 1100 nm) via various light delivery methods [1]. The safety and optimal treatment parameters of brain PBM therapy such as wavelength, fluence, power density, number of repetitions, duration of treatment, and the mode of light delivery (continuous

 

or pulsed) have been variously investigated in preclinical studies [25]. The first in vivo evidence of the neurotherapeutic effects of PBM therapy were achieved in the rabbit embolic stroke model to test its ability to prevent damage or repair damage to the brain occurring after a stroke [6]. The neuroprotective effects of laser and light emitting diodes (LED) in diverse neurological conditions such as traumatic brain injury (TBI) [7], ischemic stroke (IS) [8], Alzheimer’s disease (AD) [9], Parkinson’s disease (PD) [10], and psychological disorders such as depression and anxiety [11,12], as well as age-related cognitive decline [13,14] have been also shown.

 

The beneficial effects of PBM are mainly thought to result from the photostimulation of the mitochondrial electron transfer chain (ETC). When PBM is applied at optimum fluences (energy densities) and wavelengths, it produces therapeutic effects in the target organs without causing any adverse effects [15,16]. PBM therapy increases cerebral blood flow (CBF) [1719], augments brain energy metabolism [17,20,21] and increases antioxidant defenses [20]. Moreover, its ability to promote neuronal protection and survival is mediated through modulation of anti-apoptotic and pro-apoptotic mediators [22,23] and inflammatory signaling molecules [24,25] as well as the stimulation of neurotrophic factors [4,26,27].

2,Clinical application

Medically speaking a wide range of neurological and psychological disorders affects various cerebral structures. Recent clinical brain PBM therapy studies have been focused on conditions such as AD, PD, TBI and ischemic stroke as well as MDD. However there is also a growing interest for application of this non-invasive modality in perfectly healthy individuals to improve their cognitive abilities (cognitive enhancement)

1.1. Alzheimer’s disease

Despite the existence of several animal studies, there have only been a few studies on the efficacy of PBM therapy in AD and dementia patients. Regarding these human studies, significant improvements in sleep quality, mood states, EEG patterns as well as improved cognitive function including memory and attention, have been obtained as a consequence of NIR PBM therapy [71,195]. Besides, red laser delivered via an arterial catheter leading into the brain gave improvement of CBF in AD patient, and also resulted in a remarkable reduction of dementia scores [196].

 

2.2. Parkinson’s disease

To date, the majority of the clinical investigations revealed positive impacts of transcranial PBM therapy in conditions such as TBI, stroke and depression, in which the target area was in the cortical regions of the brain. On the other hand, PD pathogenesis is linked to abnormalities in the SNc, a midbrain structure that is located at a depth 80–100 mm from the coronal suture, below the dura. Studies have suggested that light in the NIR region may not penetrate the human brain deeper than 20 mm from the cortical surface [68]. This is considered to be a clear limitation in the application of transcranial PBM therapy in human PD. However, in the only (non-controlled, non-randomized) study in PD patients, improved motor and cognitive functions has been reported following 2 weeks of transcranial PBM therapy [197].

3.3 Traumatic brain injury

So far, although the majority of animal studies have been conducted on acute TBI models, by contrast the majority of clinical studies have been conducted on chronic TBI patients. It is quite common for humans who recover from a moderate or severe head injury to suffer from a wide variety of long-lasting symptoms including cognitive impairment (eg, poor memory, impaired executive function, and difficulties concentrating), headaches, disturbed sleep, and depression. In the early open studies in TBI, transcranial LED therapy (633/870 nm) improved self-awareness, self-regulation in social functioning and sleep quality [30,33]. The higher fluence of NIR laser resulted in greater clinical efficacy such as diminished signs of headache and improved sleep quality as well as improved cognitive and mood states in TBI patients [61]. In addition, improving the alertness and awareness in TBI patients with severe disorders of consciousness was achieved following irradiation at 785 nm, a somewhat uncommon wavelength for transcranial PBM therapy

4.4. Stroke

To date, three clinical trials, called “Neurothera Effectiveness and Safety Trials” (NEST-1 [199], NEST-2 [90], and NEST-3 [200]) have been carried out in acute stroke patients. Although the phase I and II studies showed both the safety and effectiveness of PBM therapy using 808 nm laser (applied within 24 h of stroke onset), phase III trials were disappointing and were terminated for futility at an interim analysis stage. Besides these, an effort has been made in occasional studies to show neuroprotective or neuroreparative effects of PBM therapy in chronic stroke patients via transcranial [181] and multiple area [201] irradiation methods.

 

5.5. Depression

The development of effective and sustainable treatment modalities for major depression has been a global aim for decades. To date, studies on antidepressant effects of PBM therapy have had relatively short follow-up periods and could be divided into two types of studies, patients with MDD [11,202,203] and TBI patients with comorbid depression [30,33,61]. The first study in MDD patients showed that a single-session of LED therapy alleviated depression and anxiety symptoms

810nm Photobiomodulation Machine For PBM Dementia Treatment 0

 

810nm Photobiomodulation Machine For PBM Dementia Treatment 1810nm Photobiomodulation Machine For PBM Dementia Treatment 2810nm Photobiomodulation Machine For PBM Dementia Treatment 3

Compared with other therapy method, like drugs, light therapy is the most safe and no side effects way for treatment.
Light therapy was known in medical field for a long time, especially for the red light and infrared.
All our clients feel good spirit and comfortable after using.
Our device works with 810nm infrared, it can extend through the skull into the brain, offers an unique array of neurological benefits. It usually be used for treating metastatic lesions in deep tissues as well as in bones. And also be used for cancer cell imaging, as well as circulating tumor cell detection and destruction.

1.The 810 nm wavelength has the ability to extend through the skull to the brain, promoting recovery from traumatic brain injury and reducing long-term nerve damage.
2.810nm wavelength can help patients with severe depression and anxiety
3. NIR light is absorbed by cytochrome C oxidase in mitochondria.
4. Increased blood flow, energy, neuroprotection and less inflammation.
5. treat traumatic (stroke, TBI), neurodegenerative and psychiatric diseases.

Abstract:

A new piece of equipment for LED (light emitting diode) brain photobiomodulation is introduced. Preliminary results from regional cerebral oxygen saturation and from thermography are shown before, during and after stimulation.

The procedure offers a new way to quantify the biological effects of a possible innovative therapeutic method. However further measurements are absolutely necessary.

The Brain Photobiomodulation Machine is a therapeutic instrument based on the principle of photobiomodulation. It has a good therapeutic effect on traumatic events (stroke, traumatic brain injury, and global ischemia), degenerative diseases (dementia, Alzheimer’s and Parkinson’s), and psychiatric disorders (depression, anxiety, post traumatic stress disorder)

Brain photobiomodulation (PBM) with red to near-infrared (NIR) light emitting diodes (LED) could be an innovative therapy for a variety of neurological and psychological disorders. Red/NIR light can stimulate mitochondrial respiratory chain complex IV (cytochrome c oxidase) and increase ATP (adenosintriphosphate) synthesis. In addition, light absorption by ion channels leads to the release of Ca2+ and to the activation of transcription factors and gene expression. Brain PBM therapy could improve the metabolic capacity of neurons and is able to stimulate anti-inflflammatory, anti-apoptotic and antioxidant responses as well as neurogenesis and synaptogenesis. Findings suggest that PBM may enhance, for example, the frontal brain functions of older adults in a safe and cost-effective manner.

810nm Photobiomodulation Machine For PBM Dementia Treatment 4

Note the increase in the regional cerebral oxygen saturation during and after stimulation on the left and right side.

810nm Photobiomodulation Machine For PBM Dementia Treatment 5

Results from thermal imaging of the first pilot measurement using the new stimulation helmet. Note the increase in temperature on the helmet (upper row; a before, b during, and c after stimulation) on the forehead (middle row; d–f) and on the chin (lower row; g–i).

 

Main Function

1.The 810 nm wavelength has the ability to extend through the skull to the brain, promoting recovery from traumatic brain injury and reducing long-term nerve damage.

2.810nm wavelength can help patients with severe depression and anxiety

3.NIR light is absorbed by cytochrome C oxidase in mitochondria.

4.Increased blood flow, energy, neuroprotection and less inflammation.

5.treat traumatic (stroke, TBI), neurodegenerative and psychiatric diseases.

 

Indications

  1. Traumatic events (stroke, traumatic brain injury, and global ischemia).
  2. Degenerative diseases (dementia, Alzheimer’s and Parkinson’s).
  3. Psychiatric disorders (depression, anxiety, post traumatic stress disorder).

 

Contraindication

  1. Avoid direct exposure to the eyes, pregnant woman’sabdomen, melanoma, brown spots.
  2. Taboo patients with early and middle stage malignant tumors.
  3. Contraindications to patients with acute bleeding disorders.

 

PBM therapy was developed more than 50 years ago; however, there is still no common agreement on the parameters and protocols for its clinical application. Some research teams have recommended the use of a power density of less than 100 mW/cm2 and an energy density of 4 to 10 J/cm2. Others groups recommend as much as 50 J/cm2 at the tissue surface. Parameters like wavelength, energy, flfluence, power, irradiance, pulse mode, treatment duration, and repetition rate can be applied in a wide range. Our present preliminary results showed a clear response of cerebral rSO2 in relation to the LED stimulation. However, it has to be mentioned that the temperature increased signifificantly, and these effects have to be taken into account in further studies in detail. There is also the fact that ineffective studies in cells with high mitochondrial activity appear to be due more often to over-dosing than to under-dosing. Therefore, clinical studies concerning the optimal stimulation doses are necessary.

Transcranial PBM appears promising to treat different mental diseases. Pitzschke et al. also measured light propagation in different areas of Parkinson’s disease (PD)-relevant deep brain tissue during transcranial and transsphenoidal illumination (at 671 and 808 nm) of a cadaver head and modeled optical parameters of human brain tissue using Monte-Carlo simulations. This study demonstrates that it is possible to also illuminate deep brain tissues transcranially and transsphenoidally. This opens therapeutic options for sufferers of PD or other cerebral diseases necessitating light therapy. There have been several investigations concerning possible adverse effects for LED PBM.

For example, Moro et al. explored the effects of longer term application, up to 12 weeks, of PBM (670 nm) in normal, naïve macaque monkeys. They found no histological basis for any major biosafety concerns associated with PBM delivered by an intracranial approach. Hennessy and Hamblin also pointed out the already established safety and notable lack of adverse effects of transcranial PBM. The preliminary results are very promising; however, further research work is required in order to be able to use, for example, this new kind of PBM as a therapeutic method. Many investigatorsbelieve that PBM with LED and/or laser for brain disorders will become one of the most important medical applications of light therapy in the coming years and decades.

Reference: Brain Photobiomodulation – Preliminary Results from Regional Cerebral Oximetry and Thermal Imaging

810nm Photobiomodulation Machine For PBM Dementia Treatment 6

810nm Photobiomodulation Machine For PBM Dementia Treatment 7

810nm Photobiomodulation Machine For PBM Dementia Treatment 8

Specifications

Name Brain Photobiomodulation Machine
Model GY-PDT1
LED Wavelength 810 nm
Led Quantity 256pcs
Power(total helmet) 15 W
Power(one LED) 60 mW
Power 24 mW/cm2
Certificate CE, FDA
OEM Support
Color White/Black
Option Time

6-12-18-24-30 minutes

 

 

810nm Photobiomodulation Machine For PBM Dementia Treatment 9

You Might Be Into These
Get in touch with us

Enter Your Message

sale05@sschgroup.com
michael810815
llmm928@yahoo.com.cn